ACHV trades 168.0% below Wall Street's consensus target of $13.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ACHV achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Achieve Life Sciences, Inc. (ACHV) has a Wall Street consensus price target of $13.00, based on estimates from 6 covering analysts. With the stock currently trading at $4.85, this represents a potential upside of +168.0%. The company has a market capitalization of $259M.
Analyst price targets range from a low of $13.00 to a high of $13.00, representing a 0% spread in expectations. The median target of $13.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, ACHV trades at a trailing P/E of -3.9x. Analysts expect EPS to grow +26.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
PTGXProtagonist Therapeutics, Inc. | $7.3B | $112.86 | $117.25 | +3.9% | Buy | 28.0x | 26 |
ATAIAtai Beckley N.V | $1.5B | $4.06 | $12.00 | +195.6% | Buy | — | 4 |
GFAIGuardforce AI Co., Limited | $9M | $0.41 | — | — | — | — | — |
OWLTOwlet, Inc. | $18M | $5.00 | $20.00 | +300.0% | Buy | — | 5 |
CHRSCoherus Oncology, Inc. | $181M | $1.48 | $6.02 | +306.8% | Buy | — | 16 |
PRAXPraxis Precision Medicines, Inc. | $8.2B | $282.31 | $584.00 | +106.9% | Buy | — | 16 |
CLOVClover Health Investments, Corp. | $2.6B | $5.00 | $4.47 | -10.6% | Hold | 129.2x | 9 |
MNKDMannKind Corporation | $1.2B | $3.94 | $8.50 | +115.7% | Buy | — | 19 |
AVDLAvadel Pharmaceuticals plc | $2.1B | $21.64 | $21.43 | -1.0% | Buy | 28.3x | 14 |
ABBVAbbVie Inc. | $383.2B | $216.63 | $256.92 | +18.6% | Buy | 15.2x | 41 |
Quick answers to the most common questions about buying ACHV stock.
The consensus Wall Street price target for ACHV is $13, representing 168.0% upside from the current price of $4.85. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ACHV has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $13 implies 168.0% upside from current levels.
ACHV's current price is $4.85 with a consensus target of $13 (168.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $13 for ACHV, while the most conservative target is $13. The consensus of $13 represents the median expectation. These targets typically reflect 12-month expectations.
ACHV is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ACHV stock forecast based on 6 Wall Street analysts shows a consensus price target of $13, with estimates ranging from $13 (bear case) to $13 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on ACHV, with a "Buy" consensus rating and $13 price target (168.0% upside). 6 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ACHV analyst price targets range from $13 to $13, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $13 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.